<head>
    <!-- Stylesheet -->
    <link rel="stylesheet" href="css/belief.css">
</head>
<!-- Main -->
<main>
    <div class="tabs">
        <a href="" ui-sref="INCLUSION-CRITERIA" class="tab">TRIAL DESIGN</a>
        <a href="" ui-sref="BASELINE-CHARACTERISTICS" class="tab tab--active">BASELINE CHARACTERISTICS</a>
    </div>
    <h2 class="primary">BELIEF Included Patients With R/R PTCL Who Were Representative of a Broad PTCL Patient Population</h2>
    <section class="cols">
        <div class="col">
            <h3 class="secondary-variant">BELEODAQ was studied across a range of PTCL subtypes<sup>1</sup></h3>
            <h4 class="semibold">PTCL subtypes studied<sup>1</sup></h4>
            <p class="light">(N = 120, based on central diagnosis)</p>
            <img src="assets/svg/belief-trial/baseline-pie-chart.svg" alt="PTCL Subtypes Pie Chart" />
            <h4 class="secondary-variant semibold">PTCL-NOS, AITL, and ALCL are the 3 most common subtypes of PTCL<sup>9</sup></h4>
        </div>
        <div class="col">
            <div class="row">
                <h4 class="light">The <strong>median age</strong> was <strong>64 years</strong> (range, 29-81)<sup>1,2</sup>
                </h4>
                <ul>
                    <li>
                        <h4 class="light">48% of patients (n = 62) <span class="primary semibold">≥ 65 years<sup>1</sup></span></h4>
                    </li>
                    <li>
                        <h4 class="light">10% of patients (n = 13) <span class="secondary semibold">≥ 75 years<sup>1</sup></span></h4>
                    </li>
                </ul>
            </div>
            <h4 class="semibold">Patients were treated with BELEODAQ after failing at least 1 prior systemic therapy<sup>2,*</sup></h4>
            <ul>
                <li>
                    <h4 class="light">Patients received a median of 2 prior treatments (range 1-8)</h4>
                </li>
                <li>
                    <h4 class="light">Some patients were heavily pretreated with up to 8 prior treatments</h4>
                </li>
            </ul>
            <h4 class="semibold"><span class="secondary-variant">21%</span> of patients (n = 25) underwent an HSCT before entering the BELIEF trial<sup>2</sup></h4>
            <h4 class="semibold">The BELIEF trial included patients with baseline platelet counts between ≥50,000/μL and &lt; 100,000/μL<sup>2</sup></h4>
        </div>
    </section>

    <p class="light"><sup>*</sup>Prior systemic regimens (N = 120) included 97% CHOP or CHOP-like regimens, 68% other multiagent regimens, 25% single-agent regimens, and 3% corticosteroids<sup>2</sup></p>
    <p class="light">AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; CHOP, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate, and prednisone; HSCT, hematopoietic stem cell transplantation; PTCL, peripheral T-cell lymphoma; R/R relapsed/refractory; PTCL-NOS, PTCL not otherwise speciﬁed.</p>
    <div class="button-group">
        <a href="" ui-sref="ABOUT" class="button justify-left secondary"><i class="fas fa-chevron-left"></i> About BELEODAQ</a>
        <a href="" ui-sref="ORR" class="button justify-right">Efficacy <i class="fas fa-chevron-right"></i></a>
    </div>
</main>